3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
8
Brain Neoplasms
8
Neoplasm Metastasis
4
Meningeal Carcinomatosis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Astrocytoma
1
Interventions
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
Specimen Handling
4
Gemcitabine
3
Cyclophosphamide
3
temsirolimus
2
fludarabine
2
Trastuzumab
2
Temozolomide
2
Sirolimus
2
Radiosurgery
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Leucovorin
2
Injections
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Blood Specimen Collection
2
Biopsy
2
Bevacizumab
2
Azacitidine
2
vandetanib
1
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
trastuzumab deruxtecan
×
CNS
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled